Eledon Pharmaceuticals financials
$2.50−5.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$22.9M | -$21.2M | -$21.5M | -$19.1M | -$24.7M | -$18.0M | -$24.7M | -$20.5M | -$14.5M | -$10.9M | -$10.3M | -$11.2M |
| Net income | -$30.2M | -$36.9M | -$13.1M | -$16.1M | -$10.4M | -$6.0M | -$41.7M | $54.4M | -$39.0M | -$10.3M | -$30.1M | -$9.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.27 | $-0.33 | $-0.14 | $-0.21 | $-0.13 | $-0.08 | $-0.63 | $-0.32 | $-0.92 | $-0.34 | $-1.00 | $-0.33 |
| EBITDA | -$22.9M | -$21.2M | -$21.5M | -$19.1M | -$24.7M | -$18.0M | -$24.7M | -$20.5M | -$14.5M | -$10.9M | -$10.3M | -$11.2M |
| Operating cash flow | -$22.7M | -$22.6M | -$14.1M | -$14.5M | -$17.7M | -$16.1M | -$19.0M | -$11.8M | -$7.8M | -$8.7M | -$9.1M | -$12.3M |
| Free cash flow | -$22.7M | -$22.6M | -$14.1M | -$14.5M | -$17.7M | -$16.1M | -$19.0M | -$11.8M | -$7.8M | -$8.7M | -$9.1M | -$12.3M |
| Diluted shares | 113.6M | 112.4M | 95.9M | 77.2M | 77.2M | 77.1M | 66.4M | 55.5M | 42.3M | 30.0M | 30.2M | 30.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.8M | $6.2M | $22.8M | $3.7M | $5.7M | $8.5M |
| Short-term investments | $82.0M | $104.9M | $110.5M | $89.7M | $101.8M | $116.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $126.1M | $146.7M | $169.0M | $129.9M | $144.9M | $161.3M |
| Total liabilities | $54.1M | $46.2M | $32.2M | $38.8M | $38.9M | $46.7M |
| Shareholders' equity | $33.0M | $44.8M | $81.1M | $35.4M | $50.3M | $58.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology